Information Provided By: 
Fly News Breaks for September 6, 2018
SGEN
Sep 6, 2018 | 16:10 EDT
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Seattle Genetics with a Neutral rating but raised the firm's price target on the shares to $71 from a prior target of $55. He sees Adcetris being poised for blockbuster status, but is not as convinced about the long-term adoption in first-line Hodgins Lymphoma as consensus estimates indicate.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
